Péter Reményi
About
Péter Reményi is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Infectious Diseases.
According to data from OpenAlex, Péter Reményi has authored 36 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 13 papers in Public Health, Environmental and Occupational Health and 6 papers in Infectious Diseases. Recurrent topics in Péter Reményi's work include Hematopoietic Stem Cell Transplantation (19 papers), Acute Myeloid Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (13 papers). Péter Reményi is often cited by papers focused on Hematopoietic Stem Cell Transplantation (19 papers), Acute Myeloid Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (13 papers). Péter Reményi collaborates with scholars based in Hungary, France and Italy. Péter Reményi's co-authors include Mohamad Mohty, Arnon Nagler, Myriam Labopin, Hélène Labussière‐Wallet, Gèrard Socié, Jakob Passweg, László Gopcsa, Mahmoud Aljurf, Sebastian Giebel and Ibrahim Yakoub‐Agha and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.
In The Last Decade
Péter Reményi
28 papers receiving 209 citations
Peers
Péter Reményi
A. Birgitta Versluijs Netherlands
Elena Boyakova Russia
Mahmoud Sarhan Jordan
Jérémy Delage France
Peifang Xiao China
Atelda Romano Italy
Yajing Xu China
Leonardo Javier Arcuri Brazil
Kyung Taek Hong South Korea
Lydia Foeken United States
Citations per year, relative to Péter Reményi Péter Reményi (= 1×)
peers
A. Birgitta Versluijs
Countries citing papers authored by Péter Reményi
Since
Specialization
Citations
This map shows the geographic impact of Péter Reményi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Péter Reményi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Péter Reményi more than expected).
Fields of papers citing papers by Péter Reményi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Péter Reményi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Péter Reményi. The network helps show where Péter Reményi may publish in the future.
Co-authorship network of co-authors of Péter Reményi
This figure shows the co-authorship network connecting the top 25 collaborators of Péter Reményi. A scholar is included among the top collaborators of Péter Reményi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Péter Reményi. Péter Reményi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sanz, Jaime, Myriam Labopin, Jurjen Versluis, et al.. (2025). Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. Bone Marrow Transplantation. 60(4). 529–534.
2.
Blaise, Didier, Stéfania Bramanti, Mi Kwon, et al.. (2025). Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology. 207(4). 1529–1537.
3.
Sanz, Jaime, Alexander Kulagin, Nicolaus Kröger, et al.. (2024). Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT. Blood. 144(Supplement 1). 3570–3570.
4.
Beelen, Dietrich W., Simona Iacobelli, Linda Köster, et al.. (2024). Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison. Bone Marrow Transplantation. 59(5). 670–679.
5.
Giebel, Sebastian, Myriam Labopin, Zinaida Perić, et al.. (2024). Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT. Transplantation and Cellular Therapy. 31(1). 14.e1–14.e10.
6.
Bazarbachi, Ali, Myriam Labopin, Tobias Gedde‐Dahl, et al.. (2023). Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3 -ITD and Wild-type NPM1 : A Report from the EBMT Acute Leukemia Working Party. Clinical Cancer Research. 29(21). 4441–4448.
7.
Nagler, Arnon, Myriam Labopin, Stephan Mielke, et al.. (2023). Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation. 58(7). 791–800.
8.
Nagler, Arnon, Myriam Labopin, Alexander Kulagin, et al.. (2023). Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 58(5). 552–557.
9.
Szabó, Bálint Gergely, Péter Reményi, László Gopcsa, et al.. (2023). Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study. Journal of Clinical Medicine. 12(15). 5000–5000.
10.
Gézsi, András, Tamás Masszi, Gábor Mikala, et al.. (2022). Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement. Biomedicines. 10(3). 519–519.
11.
Lakatos, Botond, Bálint Gergely Szabó, Ilona Bobek, et al.. (2022). Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. International Journal of Infectious Diseases. 125. 233–240.
12.
Lakatos, Botond, László Gopcsa, Eszter Molnár, et al.. (2020). Citokinellenes terápia az új típusú koronavírus okozta megbetegedés (COVID–19) kezelésében – tocilizumab elsőként való alkalmazása egy hazai infektológiai osztályon (A COVID–19-pandémia orvosszakmai kérdései). Repository of the Academy's Library (Library of the Hungarian Academy of Sciences).
13.
Shouval, Roni, Myriam Labopin, David Bomze, et al.. (2020). Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation. 55(12). 2244–2253.
14.
Sanz, Jaime, Myriam Labopin, Miguel Á. Sanz, et al.. (2020). Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplantation. 56(6). 1272–1280.
15.
Andrikovics, Hajnalka, András Bors, László Gopcsa, et al.. (2020). Kimérizmusvizsgálatok jelentősége allogén hematopoetikus őssejt-transzplantációt követően. 53(4). 185–192.
16.
Bors, András, László Gopcsa, Árpád Bátai, et al.. (2019). Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 55(1). 215–223.
17.
Czyż, Anna, Myriam Labopin, Sebastian Giebel, et al.. (2018). Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 93(6). 778–785.
18.
Giebel, Sebastian, Myriam Labopin, Tomasz Czerw, et al.. (2018). Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer. 106. 212–219.
19.
Varga, Gergely, Gábor Mikala, András Bors, et al.. (2017). The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. Leukemia & lymphoma. 59(3). 710–716.
20.
Beelen, Dietrich W., Rudolf Trenschel, Matthias Stelljes, et al.. (2017). Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood. 130. 521–521.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Birgitta Versluijs Breakdown of academic impact, for papers by Elena Boyakova Breakdown of academic impact, for papers by Mahmoud Sarhan Breakdown of academic impact, for papers by Jérémy Delage Breakdown of academic impact, for papers by Peifang Xiao Breakdown of academic impact, for papers by Atelda Romano Breakdown of academic impact, for papers by Yajing Xu Breakdown of academic impact, for papers by Leonardo Javier Arcuri Breakdown of academic impact, for papers by Kyung Taek Hong Breakdown of academic impact, for papers by Lydia Foeken